Evaluating the expression of heat shock protein 27 and topoisomerase II α in a retrospective cohort of patients diagnosed with locally advanced breast cancer and treated with neoadjuvant anthracycline-based chemotherapies
BackgroundNeoadjuvant anthracycline-based chemotherapy (NAC) is a major regimen for the treatment of local advanced breast cancer (LABC), while resistance to NAC remains a paramount clinical obstacle. To investigate the role of heat shock protein 27 (Hsp27) and/or topoisomerase IIα (TopoIIα) in LABC...
Main Authors: | Yixuan Zhuang, Fan Zhang, Yue Xu, Lifang He, Wenhe Huang, Chaoqun Hong, Yukun Cui |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1067179/full |
Similar Items
-
The Correlation of Fibronectin and Vimentin Expression on Anthracycline-Based Neoadjuvant Chemotherapy Response in Stage IIIA and Luminal Subtype IIIB Breast Cancer
by: Feri Nugroho, et al.
Published: (2022-12-01) -
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
by: Cheng Wang, et al.
Published: (2024-06-01) -
Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01) -
HEAT SHOCK PROTEIN 27 IN LARYNGEAL SQUAMOUS CELL CANCER TREATMENT
by: O. V. Horolec, et al.
Published: (2020-09-01) -
Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)